CD4 and neoplasm: However, by treating mice with anti‐CD8 or anti‐CD4 antibodies, FMRP‐KO showed significant reduction of CD8 T cells in the blood, strong tumor growth, short survival and the worse therapeutic effect of anti‐PD‐1.